Mouse methylome studies SRP552665 Track Settings
 
Ataxia-telangiectasia mutated kinase disruption enhances the efficacy of radiation therapy in spatially-directed diffuse midline gliomas [Brain]

Track collection: Mouse methylome studies

+  All tracks in this collection (604)

Maximum display mode:       Reset to defaults   
Select views (Help):
PMD       HMR       AMR       CpG methylation ▾       CpG reads ▾      
Select subtracks by views and experiment:
 All views PMD  HMR  AMR  CpG methylation  CpG reads 
experiment
SRX27138502 
SRX27138503 
SRX27138504 
SRX27138505 
SRX27138506 
SRX27138507 
SRX27138508 
SRX27138509 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX27138502  HMR  Brain / SRX27138502 (HMR)   Schema 
hide
 Configure
 SRX27138502  CpG methylation  Brain / SRX27138502 (CpG methylation)   Schema 
hide
 SRX27138503  HMR  Brain / SRX27138503 (HMR)   Schema 
hide
 Configure
 SRX27138503  CpG methylation  Brain / SRX27138503 (CpG methylation)   Schema 
hide
 SRX27138504  HMR  Brain / SRX27138504 (HMR)   Schema 
hide
 Configure
 SRX27138504  CpG methylation  Brain / SRX27138504 (CpG methylation)   Schema 
hide
 SRX27138505  HMR  Brain / SRX27138505 (HMR)   Schema 
hide
 Configure
 SRX27138505  CpG methylation  Brain / SRX27138505 (CpG methylation)   Schema 
hide
 SRX27138506  HMR  Brain / SRX27138506 (HMR)   Schema 
hide
 Configure
 SRX27138506  CpG methylation  Brain / SRX27138506 (CpG methylation)   Schema 
hide
 SRX27138507  HMR  Brain / SRX27138507 (HMR)   Schema 
hide
 Configure
 SRX27138507  CpG methylation  Brain / SRX27138507 (CpG methylation)   Schema 
hide
 SRX27138508  HMR  Brain / SRX27138508 (HMR)   Schema 
hide
 Configure
 SRX27138508  CpG methylation  Brain / SRX27138508 (CpG methylation)   Schema 
hide
 SRX27138509  HMR  Brain / SRX27138509 (HMR)   Schema 
hide
 Configure
 SRX27138509  CpG methylation  Brain / SRX27138509 (CpG methylation)   Schema 
    

Study title: Ataxia-telangiectasia mutated kinase disruption enhances the efficacy of radiation therapy in spatially-directed diffuse midline gliomas
SRA: SRP552665
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX27138502 Brain 0.675 10.2 41597 2065.7 119 1186.0 1448 451599.5 0.980 title: GSM8691980 K27M_612395, experimental replicate 1, Mus musculus, Bisulfite-Seq; {"source_name": "mouse brain", "tissue": "mouse brain", "genotype": "Nestin-TVA/TVA; p53-FL/FL; H3f3a-LSL-K27M/H3f3a-LSL-K27M; ATM-FL/FL", "treatment": "Irradiated", "batch": "SUS20240608012", "geo_loc_name": "missing", "collection_date": "missing"}
SRX27138503 Brain 0.690 10.6 40394 2203.6 219 1025.9 1531 363269.8 0.979 title: GSM8691981 K27M_612409, experimental replicate 2, Mus musculus, Bisulfite-Seq; {"source_name": "mouse brain", "tissue": "mouse brain", "genotype": "Nestin-TVA/TVA; p53-FL/FL; H3f3a-LSL-K27M/H3f3a-LSL-K27M; ATM-FL/FL", "treatment": "Irradiated", "batch": "SUS20240608012", "geo_loc_name": "missing", "collection_date": "missing"}
SRX27138504 Brain 0.694 9.4 41472 1625.4 159 1206.3 2177 110489.3 0.979 title: GSM8691982 K27M_612408, experimental replicate 3, Mus musculus, Bisulfite-Seq; {"source_name": "mouse brain", "tissue": "mouse brain", "genotype": "Nestin-TVA/TVA; p53-FL/FL; H3f3a-LSL-K27M/H3f3a-LSL-K27M; ATM-FL/+", "treatment": "None", "batch": "SUS20240608012", "geo_loc_name": "missing", "collection_date": "missing"}
SRX27138505 Brain 0.744 10.8 37872 1399.5 409 902.8 1878 26470.2 0.966 title: GSM8691983 K27M_612137, experimental replicate 4, Mus musculus, Bisulfite-Seq; {"source_name": "mouse brain", "tissue": "mouse brain", "genotype": "Nestin-TVA/TVA; p53-FL/FL; H3f3a-LSL-K27M/H3f3a-LSL-K27M; ATM-FL/+", "treatment": "None", "batch": "SUS20240608012", "geo_loc_name": "missing", "collection_date": "missing"}
SRX27138506 Brain 0.748 10.5 35489 1555.5 400 894.3 2615 64093.8 0.971 title: GSM8691984 nPA_612035, control replicate 1, Mus musculus, Bisulfite-Seq; {"source_name": "mouse brain", "tissue": "mouse brain", "genotype": "Nestin-TVA/TVA; p53-FL/FL; ATM-FL/FL", "treatment": "None", "batch": "SUS20240608012", "geo_loc_name": "missing", "collection_date": "missing"}
SRX27138507 Brain 0.677 9.0 40758 2801.7 262 932.1 1292 499172.0 0.972 title: GSM8691985 nPA_610705, control replicate 2, Mus musculus, Bisulfite-Seq; {"source_name": "mouse brain", "tissue": "mouse brain", "genotype": "Nestin-TVA/TVA; p53-FL/FL; ATM-FL/+", "treatment": "Irradiated", "batch": "SUS20240608012", "geo_loc_name": "missing", "collection_date": "missing"}
SRX27138508 Brain 0.671 8.8 36463 2683.3 117 1090.0 1263 609810.8 0.978 title: GSM8691986 nPA_610769, control replicate 3, Mus musculus, Bisulfite-Seq; {"source_name": "mouse brain", "tissue": "mouse brain", "genotype": "Nestin-TVA/+; p53-FL/FL; ATM-FL/FL", "treatment": "None", "batch": "SUS20240608012", "geo_loc_name": "missing", "collection_date": "missing"}
SRX27138509 Brain 0.793 8.4 35172 1496.8 344 880.2 2052 26259.0 0.968 title: GSM8691987 nPA_611271, control replicate 4, Mus musculus, Bisulfite-Seq; {"source_name": "mouse brain", "tissue": "mouse brain", "genotype": "Nestin-TVA/TVA; p53-FL/FL; ATM-FL/FL", "treatment": "Irradiated", "batch": "SUS20240608012", "geo_loc_name": "missing", "collection_date": "missing"}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.